At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 16, 2026 at 16:02 ET
Arrowhead Pharmaceuticals appointed Dr. Matt Cohen, a seasoned healthcare investor and former JP Morgan portfolio manager, to its board of directors effective June 12, 2026. The appointment is routine with standard non-employee director compensation and a sign-on RSU grant of $887,000 vesting over three years.
- Dr. Matt Cohen appointed as director effective June 12, 2026
- Cohen brings 25+ years of healthcare investing experience, currently Managing Director at Vida Ventures
- Sign-on RSU grant valued at $887,000 vesting over three years
- Standard non-employee director compensation; no family relationships or arrangements
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access